Participants 81 136 3
intensive induction therapy for acute myeloid leukaemia
Participants 569 693 6
in adult patients with previously untreated AML receiving induction therapy with idarubicin, high-dose cytarabine and etopos
Participants 701 1158 6
ng 155 randomized patients, there was no statistically significant difference in the rate of grade 3 and 4 oral mucositis (primary study endpoint) between the two treatment arms (three in palifermin arm (4%), 8 in placebo arm (10%; P = 0·21); however, when considering the severity of oral mucositis (World Health Organization grade 0-4), there was evidence of reduced rates of higher grades of oral mucositis in the palifermin arm (P = 0·0007, test f
